Update from Lexeo Therapeutics
In a webcast this morning, October 7, 2025, Lexeo Therapeutics provided a detailed review of clinical data from their gene addition therapy for FA cardiomyopathy — the SUNRISE-FA Phase 1/2 clinical trial and the Weill Cornell Medicine investigator-initiated Phase 1A trial. They also provided an update on their ongoing discussions with FDA.
Click here to access the webcast recording of the presentation.
Sandi See Tai, MD, Chief Development Officer at Lexeo Therapeutics, will participate in the FA Drug Development Pipeline Update at the FA Symposium hosted by FARA on Monday, October 13, 2025.
